{
    "nct_id": "NCT05496959",
    "official_title": "177-Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (Lunar)",
    "inclusion_criteria": "* Oligorecurrent prostate cancer as determined by the presence of 1-5 asymptomatic lesions outside the prostate or prostate bed identified on PSMA PET/CT by local readers\n* Age >= 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n* No indication for urgent or emergent radiation\n* Histologic confirmation of prostate adenocarcinoma (histology from original treatment acceptable)\n* White blood cell count >= 2.5 × 10^9/L\n* Platelets >= 100 × 10^9/L\n* Hemoglobin >= 9 g/dL\n* Total bilirubin =< 1.5 × institutional upper limit of normal (ULN); or up to 3 × ULN if known history of Gilbert's syndrome\n* Alanine aminotransferase or aspartate aminotransferase =< 3.0 × ULN or =< 5.0 × ULN for patients with liver metastases\n* Serum creatinine =< 1.5 × ULN or creatinine clearance >= 50 mL/min\n* Serum albumin > 3.0 g/dL\n* Partner and patient must use a method of birth control with adequate barrier protection, deemed acceptable by the principal investigator during the study and for 3 months after last study drug administration\n* Ability to understand, and willingness to sign, the written informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with neuroendocrine or small cell carcinoma of the prostate\n* Patients with castrate-resistant disease (i.e., PSA > 0.5 ng/mL with serum testosterone < 150 ng/dL)\n* Patients who received androgen deprivation therapy within 6 months of trial enrollment\n* Concurrent systemic therapy for a solid organ malignancy\n* Spinal cord compression\n* Inability to lie flat\n* Known hypersensitivity to components of 177Lu-PNT2002\n* Serum creatinine > 1.5 × ULN or creatinine clearance < 50 mL/min\n* Total bilirubin > 1.5 × ULN or > 3.0 × ULN if known history of Gilbert's syndrome\n* Alanine aminotransferase or aspartate aminotransferase > 3 × ULN (or 5 × ULN for patients with known liver metastases)\n* De novo oligometastatic disease",
    "miscellaneous_criteria": ""
}